Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI) announced on February 28, 2022, the approval of stock options for 168,500 shares and 112,200 restricted stock units (RSUs) to nine new employees. These awards are part of the 2022 Inducement Stock Incentive Plan and serve as an employment inducement per Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price of $10.33, vesting over four years, with specific conditions for immediate exercise upon a change in control or termination for good reason.
- Grant of stock options may enhance employee motivation and retention.
- Equity awards align employee interests with shareholder value.
- Potential dilution of shares due to stock options and RSUs.
NEWTON, Mass., Feb. 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company approved the grant of stock options to purchase an aggregate of 168,500 shares of Karyopharm's common stock and an aggregate of 112,200 restricted stock units (RSUs) to nine newly-hired employees. These equity awards were granted as of February 28, 2022 (the Grant Date) pursuant to the Company's 2022 Inducement Stock Incentive Plan, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Each of the stock options has an exercise price of
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301492068.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
What is the significance of KPTI's stock option grant on February 28, 2022?
What is the exercise price for Karyopharm's stock options?
How are KPTI's stock options structured?
What happens to stock options if there is a change in control at Karyopharm?